ESMO 2025: HER2-Targeted Therapy Advances in BTC

At ESMO in Berlin, Teresa Macarulla, MD, PhD, from Vall d’Hebron University Hospital in Barcelona, presented new data supporting HER2 as an emerging treatment target in biliary tract cancers (BTC). She reviewed updated ESMO guideline recommendations and highlighted results showing promising response rates and a manageable safety profile.